Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The new treatment was safe and may effectively treat male pattern hair loss.

This study developed a new semiquantitative grading scale for frontal and vertex androgenetic alopecia, which was found to be more sensitive and objective than existing classifications.

This study proposes a new clinical scoring method for hair density based on hair diameter diversity, which correlates with existing measures and reflects follicle miniaturization in androgenetic alopecia.

In this study, platelet rich plasma treatment showed efficacy in improving hair count, thickness, and density in male patients with androgenetic alopecia.

This paper documents a case of natural reversal of moderate-to-severe androgenetic alopecia without medical intervention, but emphasizes it is an individual observation not generalizable to broader populations.

In this documented case report, the researcher detailed a natural reversal of moderate-to-severe androgenetic alopecia without any medical interventions by systematically observing and analyzing hair regrowth over time, emphasizing that these findings are purely from personal practice and not applicable to broader populations.

This study found that androgenetic alopecia can affect the occipital region in men with advanced stages of the condition.

This study found that long-term treatment with 1 mg/day finasteride over 10 years resulted in high efficacy and prevention of disease progression in Japanese men with androgenetic alopecia, with no serious adverse reactions reported.

This study found that combining microneedling with 5% Minoxidil and Finasteride significantly improved hair density and hair shaft diameter in males with androgenetic alopecia, outperforming Minoxidil alone or in combination with Finasteride, although changes in hormonal levels and trace elements were not significant.

This study found that patients with androgenetic alopecia had significantly higher COVID-19 severity compared to matched controls, suggesting a potential link between androgen pathways and disease severity. The authors suggest further research to validate this hypothesis and explore antiandrogen treatments for managing COVID-19 severity.

In this study, injecting two different concentrations of botulinum toxin A was found to be safe and effective for treating androgenetic alopecia in Egyptian men and women, with improvements in hair grade and vellus hair density observed over six months.

This study suggests that greater sensitivity to androgens, as indicated by higher than grade 2 androgenic alopecia, may reduce the risk of schizophrenia by 8.62 times.

This study suggests that finasteride may be a safe and effective treatment for androgenetic alopecia in transgender men undergoing testosterone replacement therapy, though it may influence testosterone's effects.

This study found that men with androgenic alopecia had significantly lower hair zinc levels compared to controls, but no significant difference in blood zinc levels was observed.

In this study, significant hair loss was found to be less common among white male CEOs aged 50-69 years than in the general white male population.

This study found that significant hair loss among white male CEOs aged 50-69 years occurred less frequently than previously reported for the general white male population.

HairLossMultinet accurately classifies hair damage with 98% accuracy but needs a more diverse dataset for broader use.

This study suggests that male pattern baldness—especially moderate to severe—is an independent risk factor for prostate cancer and high-grade disease in men undergoing prostate biopsy.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

In this research, experienced clinicians noted inconsistency in the reproducibility of the commonly used Hamilton-Ludwig scales for assessing pattern hair loss severity in photographic assessments, leading to the proposal of a new 5-point scale for staging female hair loss.

This study assessed the use of oral finasteride in transgender men with androgenetic alopecia and found that all patients improved by one grade on the Norwood–Hamilton scale within about 5.5 months, with no significant adverse effects reported during the 16.2 months of follow-up.

This study developed a support vector machine model using trichoscopic patterns to accurately classify androgenic alopecia severity, with an accuracy of 94.3% in training and 90.0% in test datasets.

This study supports evaluating metabolic syndrome and insulin resistance in young males with advanced androgenic alopecia to potentially reduce future cardiovascular and type 2 diabetes risks.

This article discusses androgenetic alopecia and reports no new clinical results.

This article highlights the lack of attention to the impact of polycystic ovarian syndrome on women's identity, mental health, and quality of life in India without offering new findings.

This case study describes a patient initially misdiagnosed with pediculosis capitis, later identified as having trichotillomania, highlighting the importance of thorough behavioral inquiries by physicians in such cases.

This study describes the development of the BASP classification system, providing a universal and systematic approach for classifying pattern hair loss in both men and women.

Different factors help diagnose and treat hair loss accurately.

This study found that in Korean patients, cardiovascular disease-related risk was significantly associated with male sex, moderate to severe androgenetic alopecia, and particularly FV-type alopecia.

This review discusses the use of beard hair as a donor source for hair transplantation in hirsute patients and highlights the lack of extensive studies on its efficacy and safety in East Asian populations.